Neurobiox TM. by Beauty Creations. The Skin Biosurfacer

Transcription

1 Neurobiox TM by Beauty Creations The Skin Biosurfacer

2 We decode the message... Although plastic surgery can do wonders, some women reject it and yet manage to look younger than their age. What is their secret? Staying curious, driven, true to themselves and expressing this inner youth. Exchanges and communication are key to keep vitality and freshness. Nevertheless, cosmetic medicine has a bright future as long as women boldly turn to radical solutions including laser treatments, dermabrasion and chemical peels. These so-called «resurfacing» methods are in fashion. The term may sound alarming, but the associated techniques are highly effective. The skin looks like new: smoothed, free of wrinkles and pores, allowing patients to shed off 10 years in just a few weeks, so much that it becomes difficult to guess their age Is that the ideal of beauty we are striving for? Do we want to freeze time to create a smooth, expressionless faces with no signs of the past? Lighter cosmetic solutions including the AHA produce very good results in terms of radiance and even complexion. However, in order to deliver visible rejuvenating action, the efficient concentrations become quickly irritating. Is there a physiological solution that can make the skin reveal its faded youth and preserve a true beauty? Beauty Creations has discovered that the answer lies in the epidermis, and more specifically in the capacity of nerve cells to communicate with cutaneous cells. By decoding the exchanged message, Neurobiox stimulates epidermal regeneration and reveals a new, visibly rejuvenated skin surface. What is new in neurocosmetics? Based on claims of well-being, new product launches in neurocosmetics have mainly capitalized on the symbolic aspect of soothed, relaxed and dazzlingly radiant skin! Yet, the original connections between nerve and skin cells in the embryonal system seem to suggest that not all the aspects of neurocosmetics, by far, have been addressed: 30 to 40% of epidermal thickness is controlled by cutaneous innervation A new route for anti-age? Modulating the synthesis of neuromediators in the epidermis remains the most common goal in the field to date. But what are the visible benefits? Difficult to say... By targeting not the neuromediators, but the receptors, Neurobiox has opened a new chapter in neurocosmetics: the surface s correction.

3 Neurobiox, A unique yarrow extract The skin Biosurfacer With age, the cycle of epidermal cell renewal is prolonged, the epidermis becomes thinner and signs of aging begin to appear. Beauty Creations now offers a Achillea millefolium extract with a unique way to induce epidermal correction: the neurocutaneous exchange. Our innovation consists in the discovery of a new anti-aging receptors. target: POMC-related With age, the expression of POMC neuropeptides in the keratinocytes rises, while the expression of their receptors, namely MC-2R and MOR-1, declines: the communication between the nerve cells and the cutaneous cells is desynchronized. How can this dialog be restored and with what benefits? By stimulating the expression of these two specific receptors in keratinocytes, Neurobiox resynchronizes the balance between mediators and receptors while optimizing the transmission of the cellular message. We have demonstrated, for the first time that this communication has a direct impact on the rejuvenation of the skin surface. The results obtained show a 10% increase of the epidermal thickness together with an accelerated renewal (in vivo study). Clinical results show that after 2 months, Neurobiox gives comparable effects to glycolic acid and significantly better results versus the placebo, providing an intense antiaging action: the pores and wrinkles appearance were reduced. Renewed, the skin was significantly softer, smoother as if resurfaced. Summary file REF A00112 DESCRIPTION Neurobiox contains an aqueous extract of Achillea millefolium, commonly known as yarrow. Regulatory data INCI Water, Butylene Glycol, Pentylene glycol, Achillea Millefolium extract, Xanthan gum. Japanese cosmetic denomination Mizu, BG, Penchiren Gurikoru, Seiyounokogirisou ekisu, Kisantangamu. CAS# , , , , EINECS# , , , , preliminary SPCIFICATIONS Dry weight (15 hours, 105 C) Total Inorganic Matter Content (15 hours, 600 C) Appearance Translucent liquid Color Yellow orangey to brown Odor Characteristic ph (Direct) Refractive Index (20 C) ( ) Aerobic bacteria (30 C) < or= 100/g Pathogens None Formulation data Properties Activation of epidermal differentiation Skincare Surface rejuvenating care Texture refining serum Concentration of use 1 to 5% Incorporation method Added at the end of the formulation process, at room temperature, under gentle agitation. patent Pain S, Dezutter C, Andre V, Reymermier C, Orly I, Perrier E. MC-1 R, MC-2 R, and/or mu-opioid receptors stimulation. France (FR ), International (WO2008/148891).

4 To correct the surface... Beauty creations discovery Age-related drop in receptor expression Young skin (age 30) Mature skin (age 60) MC-2R MOR-1 Balanced mediator/receptor Unbalanced mediator/receptor Receptor Cell message transmission Neuromediator No cell message transmission... by synchronizing cells neuro-dialogue Neurobiox Rejuvenated skin surface Biosurfacing effect +10% epidermis thickness Restored cell message transmission

5 Neurobiox stimulates the synthesis of POMCrelated receptors Multiplies MOR-1 mrna expression by 22 Multiplies MC-2R mrna expression by 7 MOR-1 gene expression (% vs. untreated control) x22 Untreated control Neurobiox 0.5% MC-2R gene epression (% vs. untreated control x7 Untreated control Neurobiox 0.5% TESTED IN VITRO Quantification of MOR-1 and MC-2R mrna by quantitative RT-PCR in normal human epidermal keratinocytes (n=9). : statistically significant vs. untreated control, p<0.01 Increases the protein synthesis of MOR-1 by 3 and MC-2R by 19 Receptor Protein expression (% vs. untreated control) 20 0 UT Neurobiox 0.5% x3 x19 * MOR-1 MC-2R TESTED IN VITRO Measurement of MOR-1 and MC-2R proteins by Western-blot in normal human epidermal keratinocytes. * : statistically significant vs. untreated control, p<0.05 : statistically significant vs. untreated control, p<0.01 Neurobiox stimulates epidermal differentiation Untreated control Neurobiox 0.5% Cytokeratin µm 50 µm Increase Cytokeratin 10 expression in the deeper layers of the epidermis Filaggrin 50 µm 50 µm Increase of filaggrin expression on the surface of the epidermis TESTED EX VIvO Visualization by fluorescence microscopy of cytokeratin10 and filaggrin on aging human biopsies (age 60) after 72h of incubation with 0,5% Neurobiox. Neurobiox improves epidermal thickness 86 µm 96 µm* +10% Thickness 50 µm 50 µm Untreated control Neurobiox 0.5% TESTED EX VIVO Visualization of epidermal thickness in aging human biopsies (age 60) after 72h of incubation with 0,5% Neurobiox. * p<0.05 vs. untreated control

6 Neurobiox accelerates epidermal renewal Color variation (ΔE2) Placebo Neurobiox 2% Glycolic acid 3% Neurobiox -3,5 days vs placebo Glycolic acid -4 days vs placebo Epidermal renewal time in Days TESTED IN VIVO Estimated epidermal renewal time ΔE2 was measured at D1, D4, D5, D6 and D7 after DHA application. The estimated time when ΔE2 reaches 0 corresponds to the time when the skin regains its original color and hence also the time of epidermal renewal. Skin surface intensely rejuvenated in 56 days Wrinkles smoothed Pores refined D0 D56 Grade 5 Grade 4 Expert grading, illustrative picture of a volunteer from group 2-20% D0-18% D56 Clinical score 5.5 Clinical score 4.5 Illustrative picture of a volunteer from group 2

7 Neurobiox, The Skin Biosurfacer Neurobiox has a triple surface rejuvenation action Results in favor of Neurobiox Neurobiox is significantly better versus glycolic acid than placebo Glycolic acid 3% Neurobiox 2% Placebo Neurobiox 2% Wrinkles -6% -9% -12% -21% vs glycolic acid -14% -2% -4% * -2% -163% vs placebo -6% P O R E S -11% -14% -19% -9% vs glycolic acid -21% -9% -10% -12% -54% vs -19% placebo Softness +21% +20% +10% vs glycolic acid +28% +31% +14% +17% +22% vs placebo +19% +24% Clinical study Performed on 63 women ages 47 to 68. Tested on half-face. Evaluation at D0, D28 and D56. Group 1: Neurobiox 2% vs. Glycolic acid 3%. Group 2: Neurobiox 2% vs. placebo twice a day. Wrinkles: expert grading of crow s feet wrinkles by reference to a 9-grade photographic atlas (0 no wrinkles, 8 severe wrinkles). Pores: visual clinical evaluation. Softness: tactile clinical evaluation. * statistically significatif vs. TO, p<0.05. statistically significatif vs. TO, p<0.01. statistically significatif vs. TO, p< statistically significatif vs. placebo, p<0.05.

8 EUROPE BASF Beauty Creations 49, avenue Georges Pompidou Levallois-Perret Cedex France Tel: +33 (0) Fax: +33 (0) AMERICAS Beauty Creations BASF Corporation 50 Health Sciences Drive Stony Brook, NY USA Tel: +1 (631) Fax: +1 (631) JAPAN & ASIA-PACIFIC BASF Japan Ltd. 21F Roppongi Hills Mori Tower, Roppongi, Minato-ku, Tokyo, JAPAN Tel: +81 (0) Fax: +81 (0) Edition September 13, 2012 Although all statements and information in this publication are believed to be accurate and reliable, they are presented gratis and for guidance only, and risks and liability for results obtained by use of the products or application of the suggestions described are assumed by the user. THERE ARE NO WARRANTIES OF ANY KIND. ALL EXPRESS AND IMPLIED WARRANTIES ARE DISCLAIMED. Statements or suggestions concerning possible use of the products are made without representation or warranty that any such use is free of patent infringement and are not recommendations to infringe any patent. The user should not assume that toxicity data and safety measures are indicated or that other measures may not be required. The claims and supporting data provided in this publication have not been evaluated for compliance with any jurisdiction s regulatory requirements and the results reported may not be generally true under other conditions or in other matrices. Users must evaluate what claims and information are appropriate and comply with a jurisdiction s regulatory requirements. Recipient of this publication agrees to (i) indemnify and hold harmless each entity of the BASF organization for any and all regulatory action arising from recipient s use of any claims or information in this publication, including, but not limited to, use in advertising and finished product label claims, and (ii) not present this publication as evidence of finished product claim substantiation to any regulatory authority.